GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Gross Profit

Zealand Pharma A/S (Zealand Pharma A/S) Gross Profit : $45.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Gross Profit?

Zealand Pharma A/S's gross profit for the three months ended in Mar. 2024 was $1.53 Mil. Zealand Pharma A/S's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $45.94 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Zealand Pharma A/S's gross profit for the three months ended in Mar. 2024 was $1.53 Mil. Zealand Pharma A/S's Revenue for the three months ended in Mar. 2024 was $2.20 Mil. Therefore, Zealand Pharma A/S's Gross Margin % for the quarter that ended in Mar. 2024 was 69.50%.

Zealand Pharma A/S had a gross margin of 69.50% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Zealand Pharma A/S was 99.00%. The lowest was -374.60%. And the median was 89.75%.


Zealand Pharma A/S Gross Profit Historical Data

The historical data trend for Zealand Pharma A/S's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Gross Profit Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.09 31.40 14.83 14.81 47.35

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.96 1.51 41.55 1.35 1.53

Competitive Comparison of Zealand Pharma A/S's Gross Profit

For the Biotechnology subindustry, Zealand Pharma A/S's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Gross Profit distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Gross Profit falls into.



Zealand Pharma A/S Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Zealand Pharma A/S's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=50.153 - 2.805
=47.35

Zealand Pharma A/S's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=2.2 - 0.671
=1.53

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.94 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Zealand Pharma A/S's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1.53 / 2.2
=69.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Zealand Pharma A/S  (OTCPK:ZLDPF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Zealand Pharma A/S had a gross margin of 69.50% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Zealand Pharma A/S Gross Profit Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.